Bausch Health Companies Inc. (BHC) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-29

Key Insights

Bausch Health Companies announced Q1 2026 financial results on April 29, 2026, with the press release serving as the primary disclosure vehicle for operational performance and financial metrics.
The filing is a routine quarterly earnings announcement with limited material substance provided in the 8-K itself; substantive financial details are contained in the attached press release (Exhibit 99.1) which is not incorporated by reference and carries no liability under Section 18 of the Securities Exchange Act.
The report was signed by Jean-Jacques Charhon as Executive Vice President and Chief Financial Officer, indicating standard CFO-level certification of the earnings disclosure with no executive leadership changes noted.

Want the newest filings?

This analysis covers the filing from 2026-04-29. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-02

Bausch Health Companies Inc. (BHC) is modifying the settlement terms of certain 2023 performance share unit (PSU) awards, allowing for cash payments instead of stock upon vesting.
The changes affect awards held by two named executive officers, Thomas Appio and Seana Carson, who will receive cash payouts based on the market price of BHC's common stock on the vesting date.
This appears to be an effort by the company to provide liquidity to executives and avoid potential dilution from the settlement of PSU awards in shares.

Filed: 2026-02-18

Bausch Health Companies Inc. reported its Q4 2025 and full-year 2025 financial results, indicating continued performance with revenue and earnings growth.
The company's press release highlights ongoing business momentum, with specific details on key product lines and operational initiatives.
Investors will likely focus on the company's guidance and outlook for 2026, as well as any notable changes in the business or competitive landscape.

Filed: 2026-01-23

Bausch Health Companies announced positive results from its global Phase 3 clinical trial evaluating amorphous-rifaximin solid soluble dispersion for the primary prevention of hepatic encephalopathy in adults with liver cirrhosis, a significant milestone for the company.
The successful completion of this trial could lead to regulatory approvals and the potential launch of a new product in Bausch Health's pipeline, which could drive future revenue growth.
Investors should monitor any updates on the regulatory approval process and potential commercial launch of this new treatment, as it could have a meaningful impact on the company's financial performance.

Filed: 2026-01-13

Bausch Health is providing an update at the JPM Conference on January 14, 2026, including reaffirming its full-year 2025 guidance at the higher end of the range.
The company's management will share strategic and business updates during the presentation, which will be webcast live and available on the Investor Relations section of the company's website.
Bausch Health is cautioning investors that actual results may differ materially from the forward-looking statements due to various risks and uncertainties discussed in its previous filings.

Filed: 2026-01-02

Bausch + Lomb has refinanced its outstanding term loans, extending the maturity date to 2031 and reducing the applicable interest rate margins.
The refinancing provides Bausch + Lomb with improved financial flexibility and potentially lower borrowing costs going forward.
The press release indicates the refinancing was successfully completed, which should be viewed positively by investors.

Other reports for Bausch Health Companies Inc.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.